公开(公告)号：US09696276B2

公开(公告)日：2017-07-04

申请号：US13896765

申请日：2013-05-17

Applicant: Boston Heart Diagnostics Corporation

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N33/53 ,  G01N27/447 ,  C12M1/26

CPC classification number: G01N33/561 ,  C12M33/00 ,  G01N27/44739 ,  G01N27/44747 ,  G01N27/44778 ,  G01N33/54386 ,  G01N33/6842 ,  G01N33/92 ,  G01N2333/775 ,  G01N2550/00 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52

Abstract: Disclosed are methods and apparatus for separation of biomolecules via two-dimensional gel electrophoresis, methods and apparatus for immunoblotting separated biomolecules, and methods for the use of biomolecules processed via the methods and apparatus of the present invention, including use in a clinical setting. The methods and apparatus for separation of biomolecules via two-dimensional gel comprises vertical agarose gel electrophoresis in the first dimension, and the electrophoresis of a novel non-denaturing 3-35% concave gradient polyacrylamide gel in the second dimension. This novel gel can be cast in a modified gel caster that can facilitate the pouring of multiple gels simultaneously. The methods and apparatus for immunoblotting are useful with any type of immunoblotting, including Western blot, Northern blot, and Southern blot analyzes. These methods and apparatus provide safe, efficient and cost-effective immunoblots, while facilitating the reduction of exposure to toxic or radioactive materials, as well as the disposal of those materials.

公开(公告)号：US09817001B2

公开(公告)日：2017-11-14

申请号：US13945436

申请日：2013-07-18

Applicant: Boston Heart Diagnostics Corporation

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2800/52

Abstract: Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises methods for devising a personalized treatment plan for a patient via the use of an extended CVD risk assessment panel measuring markers of cholesterol absorption and production and HDL subfractions. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers alone, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

公开(公告)号：US20160327578A1

公开(公告)日：2016-11-10

申请号：US14706834

申请日：2015-05-07

Applicant: Boston Heart Diagnostics Corporation

Inventor： Bela F. Asztalos ,  Michael Riel-Mehan ,  Ernst J. Schaefer

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2405/00 ,  G01N2500/04 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52 ,  G16B20/00 ,  G16H50/20 ,  G16H50/30

Abstract: A method is provided for transforming one or more biomarkers into a cholesterol efflux capacity (CEC) level. Methods relate to determining SR-BI-mediated and ABCA1-mediated CEC. CEC may be used for compound screening and to determine risk of cardiovascular disease and to recommend or administer treatment regimens.

Abstract translation: 提供了将一种或多种生物标志物转化为胆固醇流出能力（CEC）水平的方法。 方法涉及确定SR-BI介导的和ABCA1介导的CEC。 CEC可用于化合物筛选和确定心血管疾病的风险，并推荐或施用治疗方案。

公开(公告)号：US20180306822A1

公开(公告)日：2018-10-25

申请号：US15808350

申请日：2018-04-09

Applicant: BOSTON HEART DIAGNOSTICS CORPORATION

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2800/52

Abstract: Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises an extended CVD risk assessment panel, combining tests for traditional and new important risk markers, and methods for devising a personalized treatment plan for a patient via the use of a CVD diagnosis and treatment protocol algorithm. The new important risk markers include HDL subpopulation profile by two-dimensional gel-electrophoresis, plasma sterols, direct measurement of sdLDL-C, determination of CRP molecular forms, glycated albumin as a percentile of total albumin, and other specialized testing pertaining to apolipoprotein E and Factor V Leiden genotyping, NT-proBNP and adiponectin. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

公开(公告)号：US20140088072A1

公开(公告)日：2014-03-27

申请号：US13945436

申请日：2013-07-18

Applicant: Boston Heart Diagnostics Corporation

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2800/52

Abstract: Disclosed is a personalized diagnostic and treatment solution for cardiovascular disease. The invention comprises an extended CVD risk assessment panel, combining tests for traditional and new important risk markers, and methods for devising a personalized treatment plan for a patient via the use of a CVD diagnosis and treatment protocol algorithm. The new important risk markers include HDL subpopulation profile by two-dimensional gel-electrophoresis, plasma sterols, direct measurement of sdLDL-C, determination of CRP molecular forms, glycated albumin as a percentile of total albumin, and other specialized testing pertaining to apolipoprotein E and Factor V Leiden genotyping, NT-proBNP and adiponectin. This solution provides a more complete risk assessment of an individual than merely measuring traditional CVD risk markers, and enables the healthcare practitioner to optimize therapy for patients with or without established CVD. This solution presents the advantages of greater accuracy, savings in time and cost over existing testing and treatment methods.

Abstract translation: 公开了一种用于心血管疾病的个性化诊断和治疗解决方案。 本发明包括扩展的CVD风险评估小组，结合传统和新的重要风险标记的测试，以及通过使用CVD诊断和治疗协议算法为患者设计个性化治疗计划的方法。 新的重要风险标记包括通过二维凝胶电泳，血浆甾醇，直接测量sdLDL-C，测定CRP分子形式，糖化白蛋白作为总白蛋白百分位数的HDL亚群体特征，以及与载脂蛋白E相关的其他专门测试 和因子V Leiden基因分型，NT-proBNP和脂连蛋白。 该解决方案为个体提供了比仅仅测量传统CVD风险标记更完整的风险评估，并使医疗保健从业者能够优化或不建立CVD患者的治疗。 该解决方案具有比现有测试和处理方法更高的精度，节省时间和成本的优点。

公开(公告)号：US20130248370A1

公开(公告)日：2013-09-26

申请号：US13896765

申请日：2013-05-17

Applicant: BOSTON HEART DIAGNOSTICS CORPORATION

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N27/447

CPC classification number: G01N33/561 ,  C12M33/00 ,  G01N27/44739 ,  G01N27/44747 ,  G01N27/44778 ,  G01N33/54386 ,  G01N33/6842 ,  G01N33/92 ,  G01N2333/775 ,  G01N2550/00 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52

Abstract: Disclosed are methods and apparatus for separation of biomolecules via two-dimensional gel electrophoresis, methods and apparatus for immunoblotting separated biomolecules, and methods for the use of biomolecules processed via the methods and apparatus of the present invention, including use in a clinical setting. The methods and apparatus for separation of biomolecules via two-dimensional gel comprises vertical agarose gel electrophoresis in the first dimension, and the electrophoresis of a novel non-denaturing 3-35% concave gradient polyacrylamide gel in the second dimension. This novel gel can be cast in a modified gel caster that can facilitate the pouring of multiple gels simultaneously. The methods and apparatus for immunblotting are useful with any type of immunoblotting, including Western blot, Northern blot, and Southern blot analyses. These methods and apparatus provide safe, efficient and cost-effective immunoblots, while facilitating the reduction of exposure to toxic or radioactive materials, as well as the disposal of those materials.

Abstract translation: 公开了通过二维凝胶电泳分离生物分子的方法和装置，用于免疫印迹分离的生物分子的方法和装置，以及使用通过本发明的方法和装置处理的生物分子的方法，包括在临床环境中的用途。 通过二维凝胶分离生物分子的方法和装置包括第一维中的垂直琼脂糖凝胶电泳和第二维中新型非变性3-35％凹梯度聚丙烯酰胺凝胶的电泳。 这种新型凝胶可以浇铸在改良的凝胶浇铸机中，可以同时使多个凝胶倾倒。 用于免疫印迹的方法和装置可用于任何类型的免疫印迹，包括Western印迹，Northern印迹和Southern印迹分析。 这些方法和设备提供安全，有效和经济有效的免疫印迹，同时有助于减少暴露于有毒或放射性物质以及处理这些材料。